bdc-1001
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 24, 2020 (NCT04278144)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- TLR7/8 agonist
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05954143 | Phase 2 | Nov 30, 2023 | Bolt Biotherapeutics, Roche |
| NCT04278144 | Phase 1 | Feb 24, 2020 | Bolt Biotherapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bolt Biotherapeutics | For profit | 2 | 2 | 2 | 2020 |
| Roche | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1